0
0.5
1
1.5
2+
Mortality
30%
Improvement
Relative Risk
Mortality, PP
91%
Ventilation
22%
Hospitalization
22%
Extended ER observation..
32%
primary
Extended ER observat.. (b)
31%
Extended ER observat.. (c)
66%
Viral clearance
-49%
Fluvoxamine TOGETHER LATE TREATMENT DB RCT
Is late treatment with fluvoxamine beneficial for COVID-19?
Double-blind RCT 1,497 patients in Brazil (January - August 2021)
Fewer hosp./ER visits with fluvoxamine (p=0.0041)
c19early.org
Reis et al., The Lancet Global Health, Aug 2021
Favors fluvoxamine
Favors control